Multi-Gene Assay Predicts Recurrence In Newly Diagnosed Breast Cancer
FOLFOX 4 Should Be First-Line Therapy For Advanced Disease, NCCTG Finds
Surgery Without Radiation Found Inadequate for DCIS
QOL With Femara Comparable To Placebo, Analysis Finds
EMEND Improved Emesis In Men And Women, Trials Find
Biopsies Could Be Reduced By Computer-Aided-Detection
Chemo+Radiation Preserves Voice, RTOG Study Finds
Low-Dose IFN Not Effective Against Melanoma, Study Finds
NeoPharm To Begin Phase III Trial For Glioblastoma
Elderly Men Say Physicians Are Recommending PSA Tests
NCI-Approved Protocols Listed
Trending Stories
- An opportunity for Trump: Position U.S. cancer science to lead the world
- Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - Grilled by Congress, Kennedy defends NIH and NCI budget cuts, freezes, and RIFs
To avoid “offending” pharma, NCI doesn’t study the causes of early-onset colon cancer, HHS secretary incorrectly alleges - NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”
